Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. Academic Article uri icon

Overview

abstract

  • Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.

publication date

  • November 1, 1990

Research

keywords

  • Antibiotics, Antineoplastic
  • Carcinoma, Renal Cell
  • Depsipeptides
  • Drugs, Investigational
  • Kidney Neoplasms
  • Peptides, Cyclic

Identity

Scopus Document Identifier

  • 0025077132

PubMed ID

  • 2084073

Additional Document Info

volume

  • 8

issue

  • 4